
Sézary syndrome (SS) is a rare form of skin cancer (T‐cell lymphoma) arising in the skin from white blood cells. Mogamulizumab therapy has been shown to increase progression‐free survival in patients with SS. The authors wanted to learn more about how mogamulizumab might improve patients’ long‐term clinical responses. In conclusion, this study provides new insights that will help manage this condition.
Like
Save
Share